Founders Fund backs Gamgee's $4M seed for AI-designed dog cancer vaccines
What's the deal? GamgeeDealroom has a profile for this one. Try Dealroom →, a startup building AI-designed personalized mRNA cancer vaccines for dogs, has raised a $4 million seed round led by Founders Fund. Angel investors joined, including Loyal's Celine Halioua, Modern Animal's Steve Eidelman, Arash FerdowsiDealroom has a profile for this one. Try Dealroom →, and Gokul RajaramDealroom has a profile for this one. Try Dealroom →.
Why now? The company grew out of a viral case: Sydney entrepreneur Paul Conyngham used AI tools to help design an mRNA vaccine for his rescue dog Rosie, who had aggressive mast cell cancer. Several tumors shrank, and OpenAI chief executive Sam Altman called it an "amazing story" to his followers.
The catch: Rosie's cancer came back. Gamgee's launch states she entered remission but relapsed following a later surgery, and the company writes about her in the past tense.
What's the endgame? Conyngham's company sequences each dog's tumor and matched healthy tissue, identifies tumor-specific neoantigens, and designs a personalized mRNA vaccine to train the immune system against those targets.
Conyngham has 17 years of machine learning experience. He paid about $3,000 to sequence Rosie's DNA at the University of New South Wales, then used ChatGPTDealroom has a profile for this one. Try Dealroom → and AlphaFoldDealroom has a profile for this one. Try Dealroom → to identify mutated proteins and GrokDealroom has a profile for this one. Try Dealroom → to design the construct. Rosie received her first injection in December 2025.
What could go wrong? Rosie's case had no control group and no way to separate the vaccine's effect from surgery, chemotherapy, or natural tumor variability. Key clinical details, including her tumor's grade, have not been made public. Conyngham has consistently declined to call it a cure.
Gamgee joined Y Combinator's Summer 2026 batch and launched publicly on August 17. Clinical studies are running in Australia with the University of New South Wales, the University of Queensland, and the Garvan Institute of Medical Research, with enrollment limited to eastern Australia.
The signal: At $4 million, the round sits in the 80th percentile for size among comparable deals — sizeable for a company whose proof point is a single, unblinded animal case that ended in relapse. It reflects investor appetite for AI-driven drug design, even where the clinical evidence remains thin.
Read more: Medical Daily
Image credit: Aiko, Thomas & Juliette+Isaac
